• Pre Clinical And Clinical Research

Video of the week | What makes measles so contagious

Just this week, Public Health England said that every one person who misses a vaccination is "one too many". There have been 795 cases of mumps in the first three months of 2019, compared with 1031 cases in the whole of 2018. Measles is not far behind in terms of making a comeback, but how does the disease get such a grip, and why does it spread so fast? Check out this video from Stat news to find out more about how measles gets a grip - and remember the most effective way to prevent it is by getting vaccinated. 

UKI2S and Innovate UK launch new £10m initiative to accelerate growth of early stage science and engineering companies

The £27m UK Innovation & Science Seed Fund (UKI2S) and Innovate UK (IUK) have launched a joint initiative, the UKI2S Innovate Accelerator. With £10m of IUK funding to be used alongside direct equity investment by UKI2S, the new scheme is designed to boost some of the UK’s most exciting young companies.

CEO Update | Monday 20 May 2019

UK life science certainly feels more Champions League Final (Spurs v Liverpool) than Eurovision (UK last place) this week. First, LifeArc has announced that it has sold most of its royalty interest in the blockbuster drug Keytruda for $1.3bn (£1.02bn) and plans to invest the windfall in developing new treatments. The sale was made to the Canada Pension Plan Investment Board, one of the world’s largest retirement funds. We were thrilled that recently-appointed LifeArc CEO, Melanie Lee, was the recipient of our lifetime achievement award at the BIA Gala Dinner in January – it’s fantastic to see her leading the way on LifeArc’s monetization process. This is great news for the UK life sciences ecosystem, research and patients. You can read more about this in the Financial Times.

Lonza chooses Synpromics’ novel inducible promoter platform to manufacture biopharmaceuticals

Synpromics Ltd, the leader in gene control, and Lonza Pharma & Biotech announce a partnership for the commercialisation of a number of inducible promoters to improve the manufacturing of biopharmaceuticals. The commercial agreement with Lonza follows the award of an Innovate UK grant to Synpromics announced on 23 April 2018. Lonza and Synpromics worked together to develop and test these innovative promoters in Lonza’s industry-leading GS Xceed® Expression System.

New report unveils a thriving service and supply sector for UK medicines discovery

New report unveils a thriving service and supply sector for UK medicines discovery Driving innovation into state-of-the-art technologies such as Artificial Intelligence and Complex Cell Models is key to maintaining the UK’s global competitiveness Today [13 May 2019], Medicines Discovery Catapult and the BioIndustry Association unveil their 2019 State of the Discovery Nation report, providing new insights into the UK’s growing medicines discovery industry.

Guest Blog | Cambridge Cancer Genomics | Making Personalised Cancer Care a Reality

One of the most high profile research fields in modern healthcare is that of cancer care. The leaps in medicine mean that in the UK, cancer survival has doubled in the last 40 years. What’s more, 50% of people diagnosed currently survive for 10 years or more (CRUK, 2010–11). These are incredible statistics that show the real-world effects of better cancer research and care. But, as the incidence of new diagnoses is rising, we need to do more.

Chief.AI and Medicines Discovery Catapult awarded funding to make AI accessible to all drug discovery researchers

‘Pay as you go’ Artificial Intelligence Chief.AI and Medicines Discovery Catapult awarded funding to make AI accessible to all drug discovery researchers Today [1 May 2019], Artificial Intelligence (AI) in drug discovery gains further support as Chief.AI and Medicines Discovery Catapult secure a grant from Innovate UK to make AI accessible to all drug discovery researchers.

Guest blog | Action Medical Research | Meet the researcher: Dr Tomoki Arichi

Inspired by the ‘amazing growth’ of a young child’s brain, Dr Tomoki Arichi wants to understand more about the impact of illness on brain development – with a grant of almost £200,000 from Action.

Medicines Discovery Catapult’s Virtual R&D Discovery Services platform announce twenty-two partnerships

Leveraging the UK’s renowned contract research sector to boost industrial growth Medicines Discovery Catapult’s Virtual R&D Discovery Services platform announce twenty-two partnerships Today [26 April 2019], Medicines Discovery Catapult announces the launch of twenty-two partnerships with UK contract research organisations (CROs). The aim is to boost UK life sciences R&D and international competitiveness by channelling high quality projects through best-in-class service providers.

Guest blog | Synthace | Engineering Science with Computer Aided Biology

Computer Aided Biology (or CAB) is a conceptual framework and an emerging ecosystem of digitally powered research tools that augment human capabilities in biological research. These tools encompass both the digital (e.g. machine learning algorithms) and the physical (lab automation) which together empower biologists to address increasingly complex biological challenges.